Abstract: Microdevices containing a chamber bound on one side by a nanoporous membrane are provided. The nanoporous membrane may contain hollow nanotubes that extend through the nanoporous membrane, from one surface to the other, and extend beyond the surface of the nanoporous membrane opposite the surface interfacing with the chamber. The nanotubes may provide a fluidic conduit between an environment external to the microdevice and the chamber, which is otherwise substantially fluid-tight. Also provided are methods of making a microdevice and methods of using the microdevices.

Abstract: The present invention generally relates to compositions, such as gels comprising steroids. In certain aspects, the steroids are modified such that they can form gels, e.g., when complexed to metal ions. In some cases, the steroids form fibers, such as nanofibers, within the gel. For instance, in one set of embodiments, a steroid may be relatively hydrophobic, and/or modified to include a phosphate moiety that is able to complex to metal ions to form the gel. In some cases, such gels may be administered to a subject, e.g., through injection. Other aspects of the invention are generally directed to methods of making or using such gels, kits comprising such gels, or the like.

Abstract: The present invention provides a composition and method for targeting hypoxic tumor areas for detection or treatment or a treatment adjuvant for cancer. Specifically, a hypoxia targeting moiety is conjugated to a polymeric micelle containing imaging agents, therapeutic agents, or therapeutic adjuvants.

Abstract: Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a propellant and at lease one medicinally active compound, said propellant comprising at least one fluoroolefin having at least two but less than seven carbon atoms.

Abstract: The present invention is directed to compositions useful in assembling vesicles. The composition comprises a first block copolymer; a plurality of first inorganic nanoparticles; a second block copolymer; and a plurality of second inorganic nanoparticles or a plurality of small molecules. The composition is characterized by the ability to self-assemble into a vesicle. Also provided is a method of making a composition for delivery of a therapeutic agent and a method of using the vesicles as imaging agents.

Abstract: The invention relates to pharmaceutical industry and discloses a method of obtaining a new pharmacologically active liposomal agent containing substances that exhibit specific pharmacological activity on peripheral vessels and cavernous bodies of a mammal. More particularly, the invention relates to a method of obtaining a pharmacologically active liposomal cytochrome c containing nitric oxide. The new liposomal agent acts as a donor of the key biologically active substance—nitric oxide (NO). A method of obtaining a pharmacologically active liposomal cytochrome c and nitric oxide complex comprises the treatment of the liposomal cytochrome c emulsion with gaseous nitric oxide (NO) until liposomal cytochrome c is completely reconstituted and the addition of an S-nitroso compound to the liposomal cytochrome c emulsion.

Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

Abstract: A pharmaceutical or nutraceutical composition having at least one inositol and resveratrol for use in a) preventive and/or curative treatment in metabolic disorders related to polycystic ovary syndrome; b) treatment to reduce symptoms associated with polycystic ovary syndrome such as menstrual cycle alterations and infertility; and/or c) to decrease glucose, triglyceride and BMI levels in subjects with metabolic syndrome.

Abstract: An orally disintegrating composition having a bimodal particle size distribution, methods for its production and use thereof are provided.

Abstract: A water-phase composition for producing microparticles includes a water-phase fluid, an amphiphilic polymer stabilizing agent, a water-phase surfactant, and an organic solvent. The amphiphilic polymer stabilizing agent can be polyvinyl alcohol. The water-phase surfactant can be polysorbate 20, polysorbate 80, poloxamer 188, or sodium dodecyl sulfate. The water-phase surfactant can be ethyl acetate, dichloromethane, chloroform, or dimethyl sulfoxide.

Abstract: Oral dosage forms that contain hydrogel-forming polymers useful for achieving sustained release of API. The formulations disclosed herein may include a hydrogel-forming polymer and a water-insoluble hydrophilic polymer, which acts as a wicking agent to draw water into the formulation. Through that wicking, water combines with the hydrogel-forming polymer to form a hydrogel, thus permitting efficient and sustained release of the API from the hydrogel-forming polymer which may act as a matrix for the API. The formulations disclosed herein are particularly useful for sustained-release of a relatively water-insoluble API, such as tamsulosin, budesonide, and pharmaceutically acceptable salts thereof.

Abstract: In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released immediately following administration and again at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released before sleep and whilst a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for an immediate, followed by a delayed release of drug.

Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of coated particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a physiologically acceptable polymer, preferably a polyalkylene oxide; and form a discontinuous phase within the matrix material; which preferably provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.; and method of using said tablet to treat pain and other conditions.

Abstract: The present invention utilises 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilises novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalised medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparatuses to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.

Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.

Abstract: Nanocapsules of bioactive compounds derived from natural products as an adjunct treatment for cancer. Nanocapsules of bioactive compounds showed synergy in the treatment of cancer therapy-induced toxicity.

Abstract: One aspect of the present invention provides: a composite capsule preparation containing tadalafil or a pharmaceutically acceptable salt thereof and tamsulosin or a pharmaceutically acceptable salt thereof, wherein the composite capsule preparation comprises, on the surface thereof, a film coating layer comprising, as a film coating material, polyvinyl alcohol (PVA) or a copolymer comprising PVA; and a preparation method therefor.

Abstract: [Problem] To provide a composition and apparatus for promoting the regeneration of bone, specifically cartilage, as well as a bone regeneration promoting method. [Solution] A bone regeneration promoting composition that includes, as active ingredients, nanobubbles of hydrogen and/or of oxygen and nitrogen. A method for promoting bone regeneration by combining the bone regeneration composition, hormesis, and spatial pressure-based therapy. A sealable chamber apparatus, the apparatus being provided with a supply means for a gas mixture of hydrogen, oxygen, and nitrogen, and a control means for the internal chamber atmospheric pressure. Additionally provided is a method for promoting bone regeneration using the apparatus.

Abstract: The present invention relates a microcapsule that comprises an active pharmaceutical ingredient and a polymeric shell comprised of polymeric materials such as polyether, polyester, polyamine, polyamide, polyurea, polyurethane, polythiocarbamate, and polythiocarbonate. The outer surface of shell comprises surface functional groups such as hydroxide, primary amine, carboxylic acid, or protected forms thereof. These surface functional groups may be reacted further with reactants to place specific organic groups on the surface of the microcapsule. Such microcapsules are prepared by a modified interfacial condensation polymerization.

Abstract: The present disclosure provides delivery systems for delivering FK506 locally to damaged nerve sites. Particulate FK506 incorporated into a fibrin gel, with the amount of FK506 sufficient to give an FK506 release rate over at least 14 days of at least 5 micrograms per milliliter of the treated tissue per day has been shown to remarkably improve axon regeneration. The delivery systems include particulate FK506 having sizes between about 500 microns to about 1 millimeter encapsulated in a fibrin matrix, powdered FK506 encapsulated within electrospun films, powdered FK506 encapsulated within a cellulose matrix, and a flexible film of small intestinal submucosa having a plurality of solid islands located on one side thereof, with each island containing a preselected amount of FK506 and a polyester.

Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Abstract: Provided are a nanocomposite including a nano-drug delivery system; and a ginseng extract or a ginsenoside isolated therefrom, and a preparation method thereof, in which the nanocomposite may be used for the prevention or treatment of cancer and inflammatory diseases. The metal nanocomposite of the present invention may be prepared in a uniform size without using an additional reducing agent or stabilizing agent in a significantly shortened time, as compared with known metal nanoparticles. Further, since the metal nanocomposite has high solubility in water and high targeting ability for cancer cells, it can be advantageously developed as drugs. Further, the metal nanocomposite exhibits high anti-cancer and anti-inflammatory activities, and thus may be usefully applied to prevention or treatment of cancer and inflammatory diseases.

Abstract: The present disclosure provides a delivery system for controlled protein release without encapsulation. Identical, burst-free, extended release profiles for three different protein therapeutics were obtained with and without encapsulation in PLGA nanoparticles embedded within a hydrogel. Using both positively and negatively charged proteins, it was shown that short-range electrostatic interactions between the proteins and the PLGA nanoparticles are the underlying mechanism for controlled release. Moreover, tunable release was demonstrated by modifying nanoparticle concentration, nanoparticle size, or environmental pH. Additionally, the utility of this system was demonstrated in vivo for BDNF delivery in a rat model of stroke. These new insights obviate the need for encapsulation and offer promising, translatable strategies for more effective delivery of therapeutic biomolecules.

Abstract: The invention relates to film-like forms of administration for the transmucosal delivery of antidiabetic peptides via the oral mucosa and to processes for the production thereof Antidiabetic peptides refers to peptides which are an active compound for the treatment of diabetes mellitus, and includes insulins, insulin analogs, incretins and incretin mimetics.

Abstract: A therapeutic kinesiology tape includes a thin stretchable, elastic substrate having a first side and a second side, and an active layer disposed on the first side of the elastic substrate. The active layer has an adhesive characteristic and includes a cannabis-based mixture. In an embodiment, the cannabis-based mixture is delivered through the skin via a plurality of small-needle arrays. The kinesiology tape is available in continuous rolls and also pre-cut strips. Additionally, permanent magnets (e.g., healing magnets, acupressure magnets) may be added to the tape.

Abstract: The methods relate to preventing photoreceptor damage caused by blue light by oral administration of a macular carotenoid composition comprising of lutein and zeaxanthin isomers. The photoreceptor damage is prevented through the upregulation of genes and protein synthesis manifested by an increase in the levels gene expression and proteins synthesis of Gnat1, Rhodopsin, NCAM, Rod arrestin, GAP-43, Nrf2, Ho-1 and decrease in the GFAP, NFkB (oxidative stress markers) in rat eye models exposed to visible blue light for various time periods and simultaneously treated with macular carotenoid compositions comprising of lutein zeaxanthin and their isomers. Methods described herein also relate to treatment of visual stress conditions by administering macular carotenoid compositions for treatment headache, blurred vision, photoreceptor degeneration, oxidative stress, endoplasmic reticulum stress and the like, which are caused due to prolonged exposure to blue light source.

Abstract: The present invention relates to a carotenoid-containing composition for use in exercise therapy for improving cognitive function, particularly exercise therapy for hippocampal neurogenesis.

Abstract: This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.

Abstract: A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.

Abstract: The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.

Abstract: The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.

Abstract: Compositions comprising 3-(diaminomethylidene)-1,1-dimethylguanidine (metformin) or a pharmaceutically acceptable salt thereof and an antibiotic are provided. The antibiotic can be a ?-lactam antibiotic, vancomycin, an aminoglycoside antibiotic, a fluoroquinolone antibiotic, metronidazole, daptomycin or ciprofloxacin. The compositions can be formulated as a controlled-release pharmaceutical tablet having a granular phase which includes metformin and the antibiotic and an extragranular phase which includes a particulate material which provides a diffusion barrier and/or controlled erosion. A method of preventing, treating or inhibiting a bacterial infection is also provided by administering the compositions to a patient in need thereof. The bacterial infection can be an extracellular bacterial infection.

Abstract: The present invention provides compositions and methods useful for treating and/or preventing Herpesviridae viral infections in a mammal. In certain embodiments, the virus comprises human cytomegalovirus.

Abstract: The present invention provides methods and compositions for repairing and/or maintaining the myelin sheath of neuronal axons in a subject. In particular, the present invention provides compositions comprising one or more TRPV1 agonists exhibiting promyelinating activity for treatment of demyelinating disorders.

Abstract: The present invention provides a compound of structural formula (1), a salt thereof for use in promoting energy expenditure and/or thermogenesis.

Abstract: The present invention relates to a pain relief composition.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.

Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurologica dyslinction.

Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.

Abstract: The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).

Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.

Abstract: The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF). More specifically, the present invention relates to a pharmaceutical composition for oral use in treating psoriasis by administering a low daily dosage in the range of 375 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.

Abstract: The present invention discloses a compound—‘ethyl gallate’ which can be used as an activity enhancer for enhancing the activity of antibiotic compositions and also overcoming drug resistance in bacteria. The compound was tested against gram negative, pathogenic bacteria viz. Pseudomonas aeruginosa and Klebsiella pneumoniae in combination with tetracycline, ciprofloxacin and chloramphenicol and found to be highly effective. The effect of the compound is due to its inhibitory action on the efflux pump of the bacteria, due to which even lower concentrations of the antibiotic compositions are highly effective in killing the bacteria. The compound thus offers the technical benefits of enhancing effects of antibiotic compositions at lower dosages and helping to overcome drug resistance in bacteria.

Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.

Abstract: The present invention relates to calpain inhibitors for use in the prevention and/or treatment of adverse ventricular remodelling. In particular, they are for use in the adverse ventricular remodelling accompanying a myocardial infarction or due to chronic hypertension. The invention also relates to particular compositions comprising these inhibitors.

Abstract: Triterpenoid drugs such as CDDO-Me can be used as to treat autoimmune diseases such as graft versus host disease, lupus, and lupus nephritis. Triterpenoid drugs can also be used to prevent the effects of an autoimmune disease.

Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject.

Abstract: A method for treating a proliferative disease, disorder, or condition comprising administering a cis-diamine platinum(II) thione complex. A cis-diamine platinum(II) thione complex and compositions containing it.